IAS/R3i Joint Consensus Meeting

Videos and Interviews from the International Atherosclerosis Society (IAS)/R3i Joint Consensus Meeting

MEETING SUMMARY

New Horizons in Residual Vascular Risk:
The Selective Peroxisome Proliferator-Activated Receptor alpha Modulator (SPPARMα) Concept

Over 50 internationally recognized experts met in Chantilly in November to discuss evidence for the SPPARMα concept, as part of a Joint Consensus between the R3i and the International Atherosclerosis Society (IAS).

Despite best evidence-based treatment including statins, high risk patients experience cardiovascular events.
This high residual vascular risk emphasizes the need for therapeutic interventions targeting other modifiable risk factors.
Peroxisome Proliferator-Activated Receptor alpha (PPARα) is a key player in the regulation of lipoprotein metabolism, beta-oxidation and inflammation, potential contributors to this risk.

Yet, it is also recognized that current PPARα agonists (fibrates) have limitations. Understanding the mechanism of PPARα activation suggests the opportunity to modulate the selectivity and potency of PPARα agonists to improve their benefit versus risk profile. This principle underpins the SPPARMα concept.

PRESENTATIONS AND INTERVIEWS

Professor Jean Charles Fruchart, President of the Residual Risk Reduction Initiative (R3i)
What is the SPPARMα concept?
What is the critical test for the SPPARMα concept?
Professor Robert H. Eckel, University of Colorado, Aurora, Colorado, USA
What does the SPPARMα concept offer for management of residual vascular risk?
Professor Hitoshi Shimano, Faculty of Medicine, University of Tsukuba, Japan
How does a SPPARMα bind to the peroxisome proliferator-activated receptor PPARα?

Reducing triglyceride-rich lipoproteins reduces cardiovascular risk

Professor Børge Nordestgaard, University of Copenhagen, Denmark
Professor Robert H. Eckel, University of Colorado, Aurora, Colorado, USA
What should clinicians measure: triglycerides or something else?
Professor Chris Packard, University of Glasgow, UK
What is on the horizon for the treatment of high triglycerides?

OMEGA-3, REDUCE-IT and VITAL Results

Patrick Duriez, Université de Lille, France
Professor Alberto Zambon, University of Padua, Italy
What is your perspective of the results of the REDUCE-IT trial with high dose eicosapentaenoic acid (fish oil)?
IAS President Professor Raul Santos, Hospital Israelita Albert Einstein, and University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil
What is your perspective of the results of the REDUCE-IT trial with high dose eicosapentaenoic acid (fish oil)?

Overview of clinical trials with a SSPARMα in patients with dyslipidaemia: Japanese and European experience

Professor Koutaro Yokote, Chiba University Graduate School of Medicine, Japan
Professor Henry Ginsberg University of Columbia, New York USA
What new approaches for managing atherogenic dyslipidaemia are on the horizon?
Professor Ruth McPherson Ruddy Canadian Cardiovascular Genetics Centre University of Ottawa Heart Institute, Ottawa, Canada
What treatments are available now for managing triglycerides – and what are the issues?

R3i & IAS PRESS CONFERENCE